Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Safety and Efficacy of Tirofiban Among Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy: A Systematic Review and Meta-analysis
Cerebrovascular Disease and Interventional Neurology
P8 - Poster Session 8 (8:00 AM-9:00 AM)
4-007
To assess the use of tirofiban in people with acute ischemic stroke with large vessels occlusion treated by endovascular therapy to evaluate whether such treatments (1) reduce the proportion of patients who die or remain dependent, and (2) are sufficiently safe for general use.

Tirofiban blocks the final common pathway of platelet aggregation and favors endogenous thrombolysis by reducing thrombus growth and preventing thrombus re-formation through competitive inhibition with fibrinogen. Currently used in clinical practice for the treatment of individuals with acute coronary syndromes and during coronary angioplasty, GP IIb-IIIa inhibitors could also be useful for the treatment of people with acute ischemic stroke.

We searched MEDLINE (1966 to June 2019) and EMBASE (1980 to June 2019) for randomized controlled trials and observational trials of tirofiban in the treatment of acute ischemic stroke with large vessels occlusion proceeded endovascular therapy. Efficacy outcomes were recanalization rate and follow-up functional outcome, safety outcomes were mortality and symptomatic intracranial hemorrhage. Review Manager 5.3 and Stata Software Package 14.0 were used to perform the meta-analysis.
We included 11 trials involving 2053 participants. A total of 769 (37.5%) patients were administrated by tirofiban peri-ET proceedings. Meta-analysis suggested that tirofiban did not increase the risk for sICH (OR 1.10; 95% CI 0.77–1.57; P = 0.61) and mortality (OR 0.86; 95% CI 0.68–1.09; P = 0.20). There was no association between the use of tirofiban and recanalization (OR 1.35; 95% CI 0.94–1.94; P = 0.11). However, standard tirofiban administration (a loading dose followed with subsequent maintenance, not a single dose) significantly increased favorable functional outcome (OR 1.52; 95% CI 1.15–1.99; P = 0.003).
Standard use of tirofiban was associated with favorable outcome in acute ischemic stroke with large vessels occlusion treated by ET. High-quality randomized-controlled trials to demonstrate the efficacy of tirofiban could be feasible and ethical.
Authors/Disclosures

PRESENTER 		No disclosure on file
QIANG DONG, PhD (Huashan Hospital Fudan University) No disclosure on file
No disclosure on file